Glycotope Presents New Data on Antibodies and Fusion Proteins Against Glycotargets at the 2022 American Association for Cancer Research (AACR) Meeting

0

Glycotope Presents New Data on Antibodies and Fusion Proteins Against Glycotargets at the 2022 American Association for Cancer Research (AACR) Meeting

Berlin, Germany, 08 April2022Glycotope GmbHa biotechnology company developing antibodies against proteins that carry tumor-specific carbohydrate structures, today announces that it will present new data at the 2022 Annual Meeting of the American Association for Cancer Research (AACR), to be held in New Orleans, USA, April 8-16, 2022.

Patrik Kehler, Scientific Director of Glycotope GmbH commented“The data presented at the AACR show the potential of targeting GlycoTargets to increase the tumor selectivity of antibodies. We will present two anti-GlycoTarget antibodies with significantly improved tumor selectivity over protein-binding antibodies, resulting in reduced binding to healthy tissues or blood cells. Additionally, we will present updated in vivo efficacy data for GT-00A x IL15, our IL-15 fusion antibody targeting TA-MUC1. GT-00A x IL15 is one of the first tumor-targeted immunocytokines and has the potential to significantly outperform non-targeted IL-15 immunocytokines, providing a much needed alternative in the treatment of several solid tumor indications.

The poster details are as follows:

Abstract number: 4542 Download here starting Friday, April 8, 1 p.m. ET / 7 p.m. CET

Title: Carbohydrate-dependent protein-binding antibodies with superior tumor specificity

Category: Poster Section 21: Antibodies and Immune Therapies

Session start time: 04/10/2022 1:30:00 PM

Session end time: 10/04/2022 17:00:00

Abstract number: 4584 Download here starting Friday, April 8, 1 p.m. ET / 7 p.m. CET

Abstracts are now available on the AACR website at www.aacr.org. Electronic posters will be available for those registered for the AACR Annual Meeting at 1:00 p.m. EDT on Friday, April 8.

Title: Preclinical characterization of GT-00A x IL15: A novel IL-15-based immunocytokine with unique tumor targeting properties

Category: Poster Section 37: Therapeutic Antibodies 1

Session start time: 04/12/2022 09:00:00

Session end time: 04/12/2022 12:30:00

Contact information:





Glycotope GmbH
Dr Patrik Kehler
CSOs
Telephone: +49 30 9489 2600
Email: [email protected]

Media Contact:
Chris Gardner, Chris Welsh
Consilium Strategic Communications
Telephone: +44 (0) 20 3709 5700
Email: [email protected]

About GT-00A x IL15

GT-00A x IL15 is a TA-MUC1 targeting the immuno-cytokine fusion antibody IL-15. Cytokines have long been used in cancer treatment to activate the immune system, but side effects and short half-life limit their therapeutic application. The concept of tumor and tumor microenvironment specific targeting to exploit the full potential of IL-15 biology is unique in the competitive field of IL-15 (super)agonists. Immunocytokine attracts and activates immune cells (eg, T and NK cells) directly to the tumor site, thereby transforming an “immune desert” into a “hot” tumor and inducing tumor cell lysis. A comprehensive set of non-clinical data is available.

About Glycotopand

Glycotope is a biotechnology company using a proprietary technology platform to develop tumor-specific monoclonal antibodies. Our antibodies target specific tumor-associated carbohydrate structures or combined protein/carbohydrate glyco-epitopes (GlycoTargets). Glycotope has to date discovered over 130 GlycoTargets with antibodies against many of these targets currently in development.

Based on their superior tumor specificity, our antibodies can be developed into an array of different modes of action, including naked antibodies, bispecifics, antibody-drug conjugates, cell therapies or fusion proteins.

Visit www.glycotope.com


Share.

About Author

Comments are closed.